• Cash receipts of $4.4M with strong net operating cash inflow of $2.0M
• Major pharma $13.8M clinical trial recruitment target of 60 patients expected to complete in Apr 2026
• Continued strong SaMD bid and tender activity, with total forward orders and pipeline exceeding $10M

Resonance Health Limited (ASX: RHT) has released its Appendix 4C and Quarterly Activities & Cashflow Report for the quarter ended 31 March 2026. The company made significant progress across its three focus areas: Clinical Trial Management CRO Services, Software-as-a-Medical-Device Image Analysis Services, and Clinical Trial Site Services. Key highlights include: cash receipts of $4.4M with strong net operating cash inflow of $2.0M; completion of recruitment for a major $13.8M pharma clinical trial; continued strong SaMD bid and tender activity with total forward orders and pipeline exceeding $10M; and the TrialsWest business performing well with the Osborne Park clinic exceeding expectations and the Mandurah clinic performing ahead of schedule. The company also appointed two experienced Non-Executive Directors to strengthen the Board. Resonance Health remains operating cash flow positive, with a solid balance sheet and strategic growth initiatives underway.

The company expects to complete the recruitment target of 60 patients for the major $13.8M pharma clinical trial in April 2026, with the first patients reaching study completion.

The company continues to execute on its strategy to grow its three core business areas, supported by a strong and growing SaMD contract pipeline, continued expansion and performance of the TrialsWest clinic network, and ongoing execution of clinical trial contracts. The recent strengthening of the Board and improved operating cash flow and balance sheet position the company well to pursue its strategic growth initiatives.